Search Results 641-650 of 9389 for driving with dementia
... dementia. Aducanumab targets amyloid plaques in the brain that are believed to be an essential component of Alzheimer's disease. But what does the approval ...
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With ...
The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.
The antibodies target unwanted excess proteins, ideally before they can kill nerve cells in the brain, explains researcher and behavioral neurologist David ...
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products ...
Evidence or diagnosis of dementia – Clinical Dementia Rating (CDR) greater than 1 at baseline. Participants who transition to Dementia or become untestable ...
Mayo Clinic researchers and collaborators have identified vascular changes in the brain associated with Alzheimer's disease.
Genome-wide association studies of late-onset Alzheimer's disease (LOAD) have identified many risk variants. The lab has assessed the association of the top ...
Is there anything you can do to reduce your risk of Alzheimer's disease? Ronald Petersen, M.D., Ph.D. Director. Mayo Clinic Alzheimer's Disease. Research ...
A multidisciplinary faculty guides research in the Mayo Clinic Alzheimer's Disease Research Center.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
The challenge ends 10/10. Your gift today can have 5X the impact on AI research and technology.